Best of ASCO® Vancouver 2024: Non-Colorectal GI Cancer – Dr. Hatim Karachiwala
OR
Co-Chairs
Dr. Sharlene Gill
Dr. Nancy Nixon
Speakers
Dr. Hatim Karachiwala
Studies/trials discussed:
- Perioperative Chemotherapy Outperforms Neoadjuvant Chemoradiotherapy as Curative Treatment of Esophageal/GEJ Adenocarcinoma in the ESOPEC Trial
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
- Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
- Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- Chemotherapy and chemoradiotherapy for adenocarcinoma of the esophagus and junction with oligometastases: Results of the TNT-OES-1 trial.
- Phase 2 Study of Induction FLOT with CROSS CRT for Esophageal Cancer
- Total Neoadjuvant Therapy for Adenocarcinoma of the OESophagus and Oesophagogastric Junction: TNT-OES-2 Trial
- TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG
- MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
- A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW)
